Ultrasound Guided Transversus Abdominis Plane (TAP) vs. Trigger Point Injection (TPI) for Abdominal Wall Pain

Ultrasound Guided Transversus Abdominis Plane Block vs. Trigger Point Injection for Abdominal Wall Pain: A Randomized Comparative Trial

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01906944

Enrollment

Registered

2013-07-24

Start date

2012-01-31

Completion date

2019-08-18

Last updated

2020-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Pain

Keywords

trigger point injection, transversus abdominis plane, abdominal wall pain

Brief summary

Patients with chronic abdominal pain- with a component of abdominal wall pain- are often treated with trigger point injections. This study will help to determine if a block within the transversus abdominis plane (TAP) will provide superior analgesic benefit to a trigger point injection as therapy for these patients.

Detailed description

Only patients referred to the Pain Clinic for abdominal trigger point injections for abdominal wall pain will be considered for study recruitment. Following informed consent, patients will complete a baseline questionnaire in the Pain Clinic which gathers basic demographic data, pain scores and functional scores. Patients will be randomized to receive either a TAP injection or a TPI. Because the TAP injection involves a larger area to be anesthetized, a larger volume of medication will be used. Thirty minutes after the injection, a sensory exam will be performed on the patient to determine the level of block. At one week, one month, three months and six months after the injection, a staff member will telephone the patient to assess how they are doing. The call will take approximately 10 minutes and will consist of relaying a pain score as well as daily functioning and sleep questions. Subjects are responsible for all clinical costs associated with the injection. There is no remuneration offered for study participation.

Interventions

DRUGBupivacaine 0.25%

Bupivacaine is a local anaesthetic drug belonging to the amino amide group.

DRUGTriamcinolone

Triamcinolone is a long-acting synthetic corticosteroid.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Only patients referred to Pain Clinic for a trigger point injection. * Non-cancer pain greater than 3 months duration. * Unilateral abdominal pain. * Positive Carnett's sign (A test in which acute abdominal pain remains unchanged or increases when the muscles of the abdominal wall are tensed.) * An identifiable abdominal trigger point.

Exclusion criteria

* History of chronic psychotic disorder. * History of dementing illness. * Active abdominal visceral disease as a known contributor of the pain. * Abdominal surgery in the past 6 months. * More than one trigger point. * Abdominal wall hernias. * BMI\>40.

Design outcomes

Primary

Measure	Time frame	Description
Change in Mean Numerical Pain Score	baseline to 6 months	Pain intensity will be assessed using the 11-point Numerical Pain Score questionnaire where 0 denotes no pain and 10 signifies the most intense pain imaginable.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026